Form 4: Marinus Pharmaceuticals Director Acquires Stock and Options

Director Marvin Johnson acquired restricted stock units and stock options in Marinus Pharmaceuticals on June 18, 2024.

Summary

• Marvin Johnson, a director of Marinus Pharmaceuticals, acquired 2,300 shares of common stock in the form of restricted stock units (RSUs) and options to purchase 10,450 shares of common stock on June 18, 2024.
• The RSUs vest in full on July 15, 2025, contingent upon Johnson's continued service with Marinus Pharmaceuticals.
• Each RSU represents the right to receive one share of common stock of the Issuer.
• The stock options have an exercise price of $1.40 and also vest fully on July 15, 2025, subject to continued service.
• Following the transaction, Johnson directly owns 14,100 shares of common stock and options for 10,450 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a routine transaction by a company director, which is neither overtly positive nor negative but suggests confidence.

Positives

• The acquisition of stock and options by a director signals confidence in the company's future prospects.

Future Outlook

The vesting of the RSUs and stock options is contingent upon the reporting person's continued service with Marinus Pharmaceuticals, Inc.

Industry Context

Form 4 filings are routine disclosures of insider transactions and are closely watched by investors for signals about management's view of the company's prospects. This filing indicates a director's increased stake in the company.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholders as it signals confidence from a company director.

Key Dates

Keywords

Marinus Pharmaceuticals, MRNS, Form 4, Director, Marvin Johnson, Stock Options, Restricted Stock Units, RSUs, Beneficial Ownership, Acquisition